Solarwinds ( SWI) was downgraded at Needham to hold from buy. Company missed expectations and has several moving parts with the MSP acquisition, Needham said. Tesla Motors ( TSLA) was upgraded at Deutsche Bank to buy from hold. $160 price target. Capitalizing on inherent advantages of electric vehicles, Deutsche Bank said. Vantiv ( VNTV) was upgraded at UBS to buy and given a $30 price target. Strong visibility and an attractive valuation, said UBS. Vantiv ( VNTV) was downgraded at Wells Fargo to market perform from outperform. Valuation call, as the company is seeing lower sales, Wells Fargo said. Vertex Pharmaceuticals ( VRTX) was downgraded at UBS to neutral and given a $83 price target. Safety concerns about VX-135, UBS said. VCA Antech ( WOOF) upgraded at Piper Jaffray to overweight from neutral. Price target was increased to $32. Favorable industry trends, improving margins, and upcoming buyback programs drive the bull case, Piper Jaffray said. Zynga ( ZNGA) was downgraded at Needham to hold from buy. Now expected to generate negative cash flow, Needham said.
Stock Comments / EPS Changes
Arch Capital Group ( ACGL) numbers were raised at UBS. Estimates were raised to reflect the second-quarter earnings beat and the expectation of higher loss reserve releases, said UBS. Price target goes to $56. Biogen Idec ( BIIB) numbers were increased at BMO Capital. Estimates were boosted through 2014. Company continues to execute well with Tecfidera, BMO Capital said. Market Perform rating and new $237 price target. BioMarin ( BMRN) estimates were raised at UBS. Reflect the earnings beat, said UBS. Price target is $67. Bristol-Myers ( BMY) estimates were cut at UBS. Estimates were reduced given the voluntary OTC recalls and investments in the Eliquis launch, said UBS. Price target is $48. Borg Warner ( BWA) numbers were raised at Citigroup. Estimates were increased given margin expansion and potential for cash deployment, said Citigroup. Price target goes to $106. Cameron International ( CAM) estimates were cut at UBS. Estimates were reduced given integration delays with OneSubsea, said UBS. Price target is $75. Chubb Corp. ( CB) estimates were raised at UBS. Reflect the second-quarter beat and a decrease in the combined ratio outlook, said UBS. Price target is $96.